Insulin lispro protamine biosimilar(50R) (Wanbang Pharma)

精蛋白锌赖脯胰岛素生物类似药(50R)(万邦生化)

Report date: 2024/06/04 16:17:43

Base Information

Drug NameInsulin lispro protamine biosimilar(50R) (Wanbang Pharma)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2024/05/21
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesFosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A